Philips Demonstrates Innovation Leadership, Tops European Patent Office Medtech Filings in 2024
Amsterdam, the Netherlands – March 25, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a prominent health technology company, announced it led medical technology filings at the European Patent Office (EPO) in 2024, submitting 594 Medtech patent applications. This achievement underscores the company’s dedication to transforming healthcare through the integration of informatics and AI to improve workflows, elevate the quality of care, and reduce costs per patient.
Philips Logo
With a history spanning 134 years of innovation and global research and development programs, Philips’ innovations enhanced the health and well-being of nearly 2 billion individuals in 2024. This progress keeps the company on track to meet its 2030 goal of improving 2.5 billion lives.
Roy Jakobs, CEO of Royal Philips, stated, “For over 130 years, Philips has been at the forefront of innovations improving people’s lives. The 2024 European patent rankings highlight our continued innovation in hospitals and homes, helping deliver better care to more people. To continue driving greater impact, we have shifted our innovation closer to customers, to help healthcare professionals improve patient care and empower people everywhere to take care of their health and well-being.”
As informatics and AI become increasingly valuable in healthcare, approximately half of Philips’ R&D investments are focused on these technologies. Some of the AI-powered innovations launched in 2024 include:
- The new Azurion image-guided therapy system, featuring advanced informatics to enhance minimally invasive diagnosis and treatment for stroke and other neurovascular patients.
- FDA-cleared AI tools integrated into the EPIQ CVx and Affiniti CVx ultrasound systems, which advance cardiovascular imaging and enhance automation and productivity, solidifying Philips’ leading position in cardiovascular ultrasound.
- The new Philips Spectral CT 7500 RT, designed for personalized radiation therapy planning to provide superior care to more cancer patients.
- FDA approval for the LumiGuide Navigation Wire, which utilizes fiber optic technology to reduce radiation exposure for both patients and physicians during minimally invasive surgery.
In total, Philips filed 1,231 European patent applications across various domains, the most of any Dutch company and a testament to their consistent ranking among the top applicants since the EPO began publishing rankings in 2004. The company’s recent inclusion in the Clarivate Top 100 Global Innovators 2025 marks its 12th consecutive appearance in this major assessment of global innovation.
In 2024, Philips invested about EUR 1.7 billion in research and development to drive better care for more people. This investment represents over 9% of sales, a figure well above the industry average. The company’s comprehensive intellectual property portfolio includes 50,500 patent rights, 30,500 trademarks, 150,000 design rights, and 3,200 domain names.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a global leader in health technology, committed to improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovations leverage advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
